IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 76-100 out of 1213.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

Public Release: 21-Jan-2015
Science
NFCR-supported research finds new way to combat resistant cancers
A team of researchers at Massachusetts General Hospital has developed a new platform that can rapidly identify effective drug combinations for lung cancer patients whose tumors have stopped responding to targeted therapy. The research, which was supported in part by the National Foundation for Cancer Research, is a critical milestone on the road to personalized medicine.
National Foundation for Cancer Research

Contact: Adam Belmar
abelmar@qga.com
202-429-4015
The Science Coalition

Public Release: 21-Jan-2015
Molecular Therapy--Oncolytics
The immune system may play a key role in viral therapy's effectiveness against tumors
Viral therapy for childhood cancer could possibly improve if treatments such as chemotherapy do not first suppress patients' immune systems, according to findings published today in the journal Molecular Therapy--Oncolytics. Research on mouse tumors resembling rhabdomyosarcoma, the most common soft tissue sarcoma in children, revealed that the immune system's T cells may be just as critical to fighting tumor cells as the viral therapy injections themselves.

Contact: Gina Bericchia
MediaRelations@NationwideChildrens.org
614-355-0495
Nationwide Children's Hospital

Public Release: 21-Jan-2015
Nature Communications
Mutated ATRX gene linked to brain tumors potential biomarker for rare adrenal tumors too
For the first time, researchers at Penn's Abramson Cancer Center have found that a mutation in the ATRX may serve as a much-needed biomarker for the pheochromocytomas and paragangliomas that become malignant. These rare neuroendocrine tumors are typically benign, but when they go rogue, they become very aggressive.
PheoPara Alliance, The North American Neuroendocrine Tumor Society Early Career Development Award, National Center for Research Resources, National Center for Advancing Translational Sciences

Contact: Steve Graff
stephen.graff@uphs.upenn.edu
215-349-5653
University of Pennsylvania School of Medicine

Public Release: 21-Jan-2015
Journal of Urology
Close monitoring of renal tumors may provide alternative to surgery
In patients likely to have surgery, close, active monitoring of small renal tumors confined to the kidneys is associated with low rates of tumor growth or death.

Contact: David Slotnick
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine

Public Release: 20-Jan-2015
Journal of Clinical Oncology
ASCO names Cancer Advance of the Year
The American Society of Clinical Oncology for the first time announced its cancer Advance of the Year: the transformation of treatment for the most common form of adult leukemia. Until now, many patients with chronic lymphocytic leukemia have had few effective treatment options. Four newly approved therapies, however, are poised to dramatically improve the outlook for patients with the disease.

Contact: Kelly Baldwin
kelly.baldwin@asco.org
571-483-1365
American Society of Clinical Oncology

Public Release: 20-Jan-2015
The Lancet
How to attack and paralyze myeloma cells
Professor Martin Bornhäuser and Dr. Christoph Röllig, both experts in the field of blood cancer at the Carl Gustav Carus Medical Faculty of the TU Dresden, have now turned their long-term clinical and research experience in treatment of multiple myeloma into an instructive review for other physicians.

Contact: Dr. Christoph Röllig
christoph.roellig@uniklinikum-dresden.de
49-351-458-3775
Technische Universität Dresden

Public Release: 20-Jan-2015
Journal of the National Cancer Institute
Coffee may be associated with a lower risk of malignant melanoma
Both epidemiological and pre-clinical studies have suggested that coffee consumption has a protective effect against non-melanoma skin cancers. However the protective effect for cutaneous melanoma (malignant and in situ) is less clear, according to a study published Jan. 20 in the JNCI: Journal of the National Cancer Institute.

Contact: Zachary Rathner
Zachary.Rathner@oup.com
919-677-2697
Oxford University Press USA

Public Release: 20-Jan-2015
Proceedings of the National Academy of Sciences
New cancer-fighting strategy would harden cells to prevent metastasis
Existing cancer therapies are geared toward massacring tumor cells, but Johns Hopkins researchers propose a different strategy: subtly hardening cancer cells to prevent them from invading new areas of the body. They devised a way of screening compounds for the desired effect and have identified a compound that shows promise in fighting pancreatic cancer. Their study appears this week in the early edition of the Proceedings of the National Academy of Sciences.
NIH/National Institute of General Medical Sciences, NIH/National Institute of Allergy and Infectious Diseases, NIH/National Cancer Institute, Sol Goldman Pancreatic Cancer Center

Contact: Shawna Williams
shawna@jhmi.edu
410-955-8236
Johns Hopkins Medicine

Public Release: 20-Jan-2015
Journal of Clinical Investigation
Gene therapy-associated cancer incidence depends on vector design
A new publication in the Journal of Clinical Investigation reveals that AAV vector design influences the likelihood of developing cancer in the liver.
NIH/National Human Genome Research Institute, National Institutes of Health

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 20-Jan-2015
Journal of Clinical Investigation
Metabolic enzyme is upregulated in patients with non-small cell lung cancer
A new study in the Journal of Clinical Investigation identifies a metabolic enzyme that is upregulated in patients with non-small cell lung cancer.
National Science Foundation, NIH/National Center for Research Resources, Kentucky Lung Cancer Research Program, Kentucky Challenge for Excellence, Drive Cancer Out Campaign

Contact: Corinne Williams
press_releases@the-jci.org
Journal of Clinical Investigation

Public Release: 20-Jan-2015
New antibodies for cancer treatment
A research team at Aarhus University, Denmark, has developed 10 new antibodies that can possibly be used in the battle against cancer. They work by inhibiting the body's blood vessel formation close to the tumor, which is thereby cut off from oxygen and nutrient supply. Up to now, the researchers have tested some of the antibodies on mice and, in the laboratory they have succeeded in using them to stop the development of malignant tumors.
Danish Council for Independent Research, European Research and Technological Development 6th Framework Program, European Union, and others

Contact: Peter Kristensen
pk@eng.au.dk
45-20-36-90-97
Aarhus University

Public Release: 20-Jan-2015
Neuro-Oncology
Drug targets identified through cell line to potentially treat rare pediatric cancer
A team of investigators have made key new findings about an extremely rare childhood cancer called neurocutaneous melanocytosis. This malignant cancer is characterized by an excessive growth of melanin-producing cells in both the skin and the brain. The study's authors found potential drug targets for the disease by using a molecular analysis of patient tumor cells grown in animal models.
Alberta Children's Hospital Foundation, Kids Cancer Care Foundation of Alberta, POETIC Foundation, Nevus Outreach

Contact: Marta
mcyperli@ucalgary.ca
403-210-3835
University of Calgary

Public Release: 20-Jan-2015
Cancer
Equation helps identify global disparities in cancer screening and treatment
In a new study on colorectal cancer, researchers found that the mortality-to-incidence ratio can help identify whether a country has a higher mortality than might be expected based on cancer incidence.

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley

Public Release: 20-Jan-2015
Journal of Clinical Oncology
TGen-led study of rare ovarian cancer featured in ASCO 'Cancer Advances' annual report
A groundbreaking TGen-led discovery of the likely genetic cause of an ovarian cancer that strikes young women and girls is featured today in the annual report of the American Society of Cancer Oncology (ASCO). The discovery by an international team led by TGen, the Translational Genomics Research Institute, is included in Clinical Cancer Advances 2015: ASCO's Annual Report on Progress Against Cancer.
Lynn and Foster Friess, The Marsha Rivkin Center for Ovarian Cancer Research, The Anne Rita Monahan Foundation, The Ovarian Cancer Alliance of Arizona, The Small Cell Ovarian Cancer Foundation, TGen Foundation

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute

Public Release: 20-Jan-2015
Journal of Clinical Investigation
NIH researchers tackle thorny side of gene therapy
National Institutes of Health researchers have uncovered a key factor in understanding the elevated cancer risk associated with gene therapy. They conducted research on mice with a rare disease similar to one in humans, hoping their findings may eventually help improve gene therapy for humans. Researchers at the National Human Genome Research Institute, part of NIH, published their research in the Jan. 20, 2015, online issue of the Journal of Clinical Investigation.
NIH/National Human Genome Research Institute

Contact: Raymond MacDougall
macdougallr@mail.nih.gov
301-443-3523
NIH/National Human Genome Research Institute

Public Release: 20-Jan-2015
Advanced Materials
One nanoparticle, 6 types of medical imaging
Using two biocompatible parts, University at Buffalo researchers and their colleagues have designed a nanoparticle that can be detected by six medical imaging techniques: computed tomography scanning; positron emission tomography scanning; photoacoustic imaging; fluorescence imaging; upconversion imaging; and Cerenkov luminescence imaging.
National Science Foundation, National Institutes of Health, American Cancer Society, Natural Science Foundation of China, Program for the Basic Research Excellent Talents in Harbin Institute of Technology, and others

Contact: Charlotte Hsu
chsu22@buffalo.edu
716-645-4655
University at Buffalo

Public Release: 20-Jan-2015
IEEE Transactions on Biomedical Engineering
Scientists invent system to improve effectiveness of cancer surgery
With the goal of making it easier for surgeons to detect malignant tissue during surgery and hopefully reduce the rate of cancer recurrence, scientists have invented a new imaging system that causes tumors to 'light up' when a hand-held laser is directed at them.

Contact: Karen Richardson
klrichardson1@live.com
336-716-4453
Wake Forest Baptist Medical Center

Public Release: 19-Jan-2015
British Journal of Sports Medicine
UEA research shows group walking cuts risk of life-threatening conditions
Risk of stroke, coronary heart disease, depression and other life-threatening conditions can be reduced through regular outdoor walking in groups, according to research from the University of East Anglia. Findings published today in the British Journal of Sports Medicine reveal that people who regularly walk in groups have lower blood pressure, resting heart rate and total cholesterol.
Centre for Diet and Activity Research

Contact: Laura Potts
laura.potts@uea.ac.uk
44-016-035-93007
University of East Anglia

Public Release: 19-Jan-2015
JAMA Internal Medicine
Couples more likely to get healthy together
People are more successful in taking up healthy habits if their partner makes positive changes too, according to research published in JAMA Internal Medicine today.
Cancer Research UK, British Heart Foundation, NIH/National Institute on Aging

Contact: Stephanie McClellan
stephanie.mcclellan@cancer.org.uk
44-203-469-5314
Cancer Research UK

Public Release: 19-Jan-2015
Nature Genetics
Researchers open 'Pandora's box' of potential cancer biomarkers
Researchers at the University of Michigan Comprehensive Cancer Center analyzed the global landscape of a portion of the genome that has not been previously well-explored. This analysis opens the door to discovery of thousands of potential new cancer biomarkers.
NIH/National Cancer Institute, Department of Defense, Prostate Cancer Foundation, Howard Hughes Medical Institute, American Cancer Society, A. Alfred Taubman Medical Research Institute

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 19-Jan-2015
Archives of Biochemistry and Biophysics
Citrus scent inhibits liver cancer
As main component of essential oils, terpenes can inhibit the growth of different cancer cells. Researchers from the Ruhr-University Bochum headed by Prof Dr Hanns Hatt have analysed this process in liver cancer cells in detail. They shed light upon the molecular mechanisms that resulted in cancer cells stop growing, following the application of (-)-citronellal, and they proved that the olfactory receptor OR1A2 is the crucial molecule for that purpose.

Contact: Hanns Hatt
hanns.hatt@rub.de
49-234-322-4586
Ruhr-University Bochum

Public Release: 19-Jan-2015
Cell Reports
Twist1: Complex regulator of cell shape and function
Transcription factor Twist1 is involved in many processes where cells change shape or function. Thereby, Twist1 is crucial for embryonic development, but has also been implicated in cancer progression. However, the precise contribution of Twist1 to these processes is under much debate. Scientists from the Helmholtz Zentrum München describe a new mode of action: a short-term, transient activation of Twist1 primes cells for stem cell-like properties. By contrast, prolonged, chronic Twist1 activity suppresses stem cell-like traits.

Contact: Christina Scheel
christina.scheel@helmholtz-muenchen.de
49-089-318-72012
Helmholtz Zentrum München - German Research Center for Environmental Health

Public Release: 17-Jan-2015
2015 Gastrointestinal Cancers Symposium
Journal of Clinical Oncology
SPECTAcolor viable next generation multinational cancer clinical trial infrastructure
SPECTAcolor's successful start has demonstrated its viability to facilitate next generation cancer clinical trials. Successfully implemented across 19 clinical centers located in nine countries in Europe, it has now recruited over 500 patients since launch in September 2013. Pathological review and core analyses of tumor blocks shipped to the central biobank deemed over 98 percent of the samples were adequate. This demonstrates the feasibility of this logistically complex infrastructure for conducting multinational next generation trials.
EORTC Charitable Trust, Corporate Social Responsibility Program of Alliance Boots

Contact: John Bean
john.bean@eortc.be
European Organisation for Research and Treatment of Cancer

Public Release: 15-Jan-2015
Nature Immunology
Tumor suppressor protein plays key role in maintaining immune balance
St. Jude Children's Research Hospital scientists have discovered that a protein widely known for suppressing tumor formation also helps prevent autoimmune diseases and other problems by putting the brakes on the immune response. The research was published recently online ahead of print in the scientific journal Nature Immunology.
National Institutes of Health, American Cancer Society, Crohn's & Colitis Foundation of America, Arthritis Foundation, ALSAC

Contact: Carrie Strehlau
carrie.strehlau@stjude.org
901-595-2295
St. Jude Children's Research Hospital

Public Release: 15-Jan-2015
Journal of Chemical Theory and Computation
Shining a light on quantum dots measurement
Using the cadmium selenide quantum dot, researchers at Syracuse University collaborated to understand how protein corona forms and what is different about the quantum dot before and after the formation of the corona.
National Science Foundation, Syracuse University

Contact: Matt Wheeler
mrwheele@syr.edu
215-443-4777
Syracuse University

Showing releases 76-100 out of 1213.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 > >>

  Search News Releases

     

 

EurekAlert!